The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients

Zhai, Xuechao; Zhang, Jian; Tian, Yaru; Li, Ji; Wang, Jing; Guo, Hongbo; Zhu, Hui

doi:10.20892/j.issn.2095-3941.2020.0102

Cited by 62 publications

(62 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The definition of CIP is the occurrence of respiratory symptoms/ signs related to a new emerging infiltration viewed on a chest X-ray but excluding new infections tested by sputum and/or bronchoalveolar lavage (BAL) (5). In different tumor types, the overall incidence of CIP varied from 3% to 5% for all grades and ranged from 0.8% to 1.0% for grade ≥ 3 CIP (5,14,25,26). The overall fatality rate of CIP was 10% to 17%.…”

Section: Incidence and Onset Of Cipmentioning

confidence: 99%

“…In advanced NSCLC, an increasing body of clinical studies suggests that the application of ICIs could achieve significant breakthroughs in PFS and OS (10)(11)(12)(13). Therefore, the US Food and Drug Administration has rapidly incorporated ICIs into firstline therapies for advanced NSCLC (14). In the PACIFIC regimen, durvalumab (a PD-L1 inhibitor) has become the new standard of care after platinum-based chemoradiotherapy for unresectable stage III NSCLC in the United States, Europe, and Japan (15).…”

Section: Introductionmentioning

confidence: 99%

“…Since before ICI therapies, pulmonary function has been compromised by tumor location and size in patients with NSCLC. In addition, preexisting lung comorbidities, such as chronic inflammatory respiratory diseases, interstitial fibrosis lung diseases, and radiation-induced pneumonitis (RIP), may cloud diagnostic accuracy because of the overlapping respiratory symptoms and signs (5,6,9,14,23). As a result, recognizing the unique clinical and imaging patterns of CIP is essential to facilitate expeditious diagnosis and optimized management principles.…”

Section: Introductionmentioning

confidence: 99%

“…Although previous studies have elucidated the incidence, potential mechanisms, diagnosis, risk factors, and management of CIP, they focused on variable focuses that were not comprehensive and deep enough (5,6,9,14,23,24). This review offers a summary of cases or case series concerning CIP in NSCLC, and it aims to identify the characteristics of typical patients who develop CIP.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

et al. 2021

View full text Add to dashboard Cite

Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death- ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has revolutionized the therapeutic strategy in multiple malignancies. Although it has achieved significant breakthrough in advanced non-small cell lung cancer patients, immune-related adverse events (irAEs) including checkpoint inhibitor pneumonitis (CIP), are widely reported. As the particularly worrisome and potentially lethal form of irAEs, CIP should be attached more importance. Especially in non-small cell lung cancer (NSCLC) patients, the features of CIP may be more complicated on account of the overlapping respiratory signs compromised by primary tumor following immunotherapy. Herein, we included the previous relevant reports and comprehensively summarized the characteristics, diagnosis, and management of CIP. We also discussed the future direction of optimal steroid therapeutic schedule for patients with CIP in NSCLC based on the current evidence.

show abstract

Section: Incidence and Onset Of Cipmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Anti-PD-1 treatment can drive the activation of TILs that have otherwise lost their immunoreactive functionality, thereby restoring their proliferation and cytotoxicity such that the prognosis of treated treatment of NSCLC patients can be significantly improved (102,103). Checkpoint inhibitor pneumonia (CIP) is a particularly dangerous form of immune-related adverse events (IrAE) that can arise in NSCLC patients receiving anti-PD-1/PD-L1 therapy (104,105). Wang et al discovered that the occurrence of CIP changes the proportion of T cell subsets in plasma, thereby promoting increased secretion of IL-35 in plasma and BALF (106).…”

Section: Exploration Of Il-35 and Pd-1/pd-l1 In Cancer Immunotherapymentioning

confidence: 99%

IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment

et al. 2021

View full text Add to dashboard Cite

Interleukin-35 (IL-35) is a heterodimeric cytokine composed of Epstein-Barr virus-induced gene 3 (EBI3) and IL-12p35 that has recently been shown to play diverse and important roles in the tumor microenvironment (TME). Owing to its immunosuppressive activity and ability to promote tumor growth and progression, IL-35 is widely recognized as a key mediator of TME status. Immune cells are key mediators of diverse tumor-related phenotypes, and immunosuppressive cytokines such as IL-35 can promote tumor growth and metastasis in TME. These influences should be considered together. Since tumor immunotherapy based on immune checkpoint blockade remains ineffective in many patients due to tumoral resistance, a new target or efficacy enhancing factor is urgently needed. Suppressing IL-35 production and activity has been demonstrated as an effective factor that inhibits tumor cells viability, and further investigation of this cytokine is warranted. However, the mechanistic basis for IL-35-mediated regulation of immune cells in the TME remains to be fully clarified. In the present review, we explore the roles of IL-35 in regulating immune cells within the TME. In addition, we highlight IL-35 as a specific immunological target and discuss its possible relevance in the context of immunotherapy. Lastly, we sought to summarize potential future research directions that may guide the advancement of current understanding regarding the role of this important cytokine as a regulator of oncogenesis.

show abstract

Asiaticoside Inhibits Growth and Metastasis in Non‐Small Cell Lung Cancer by Disrupting EMT via Wnt/β‐Catenin Pathway

Zhang,

Liu,

Yang

et al. 2024

Environmental Toxicology

View full text Add to dashboard Cite

Non‐small cell lung cancer (NSCLC) is the primary inducer of cancer‐related death worldwide. Asiaticoside (ATS) is a triterpenoid saponin that has been indicated to possess an antitumor activity in several malignancies. Nonetheless, its detailed functions in NSCLC remain unclarified. In this study, NSCLC cells were exposed to various doses of ATS. Functional experiments were employed to estimate the ATS effect on NSCLC cell behaviors. Western blotting was implemented for protein expression evaluation. A xenograft mouse model was established to assess the ATS effect on NSCLC in vivo. The results showed that ATS restrained NSCLC cell proliferation, cell cycle progression, migration, and invasiveness. ATS reversed TGF‐β‐induced promotion in epithelial‐mesenchymal transition (EMT). Mechanistically, ATS inhibited Wnt/β‐catenin signaling in NSCLC. Upregulating β‐catenin restored ATS‐mediated suppression of NSCLC cell aggressiveness. Moreover, ATS administration repressed tumorigenesis in tumor‐bearing mice. In conclusion, ATS represses growth and metastasis in NSCLC by blocking EMT via the inhibition of Wnt/β‐catenin signaling.

show abstract

The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients

Cited by 62 publications

References 110 publications

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment

Asiaticoside Inhibits Growth and Metastasis in Non‐Small Cell Lung Cancer by Disrupting EMT via Wnt/β‐Catenin Pathway

Contact Info

Product

Resources

About